Advertisement

Bladder tumor Resection Weight as a Prognostic Factor for Recurrence and Progression in Patients With High-Risk Non-Muscle Invasive Bladder Treated With BCG

  • Oliver C. Hald
    Affiliations
    Department of Urology, Royal Bournemouth Hospital, University Hospitals Dorset NHS Foundation Trust, Castle Lane East, Bournemouth, UK

    Urology Centre, Guy's Hospital, Guys and St Thomas' NHS Foundation Trust, Great Maze Pond, London, UK
    Search for articles by this author
  • Yih Chyn Phan
    Affiliations
    Department of Urology, Royal Bournemouth Hospital, University Hospitals Dorset NHS Foundation Trust, Castle Lane East, Bournemouth, UK

    Department of Urology, Salisbury District Hospital, Salisbury NHS Foundation Trust, Salisbury, UK
    Search for articles by this author
  • Charles J.M. Carter
    Affiliations
    Department of Urology, Royal Bournemouth Hospital, University Hospitals Dorset NHS Foundation Trust, Castle Lane East, Bournemouth, UK
    Search for articles by this author
  • Tobias Klatte
    Correspondence
    Address for correspondence: Tobias Klatte, Department of Urology, Charité-Universtitätsmedizin Berlin, Charitéplatz 1, 10115, Berlin, Germany.
    Affiliations
    Department of Urology, Royal Bournemouth Hospital, University Hospitals Dorset NHS Foundation Trust, Castle Lane East, Bournemouth, UK

    Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany
    Search for articles by this author
Published:August 29, 2022DOI:https://doi.org/10.1016/j.clgc.2022.08.007

      Abstract

      Introduction

      Predicting outcomes of patients with high-risk non-muscle invasive bladder cancer (HR-NMIBC) is critical. Here, we evaluate whether bladder tumor resection weight might serve as a prognostic factor for recurrence and progression of HR-NMIBC patients treated with Bacillus Calmette-Guérin (BCG).

      Methods

      In this retrospective, single-centre study in the UK, we analysed a consecutive cohort of HR-NMIBC patients who have received adequate intravesical BCG immunotherapy between 2009 and 2019. Univariable and multivariable Cox proportional hazards models were used to assess the association of resection weight and established predictors with recurrence and progression.

      Results

      A total of 187 HR-NMIBC patients were analysed. The median resection weight was 1.4g (range: 0.2-28.5g). Within a median follow-up of 41 months, 58 (31%) tumors recurred and 19 (10%) progressed. Fifty-four patients (29%) died from any cause and 16 (9%) died from bladder cancer. Both the risk of recurrence (P = .007) and progression (P = .019) increased with rising resection weight. On the multivariable analysis, a resection weight of ≥ 2g and ≥ 3g conferred a 4.35-fold and a 9.03-fold increased risk of bladder cancer recurrence (P < .001) and progression (P < .001), respectively. The addition of resection weight improved the C index of multivariable standard prognostic models to a clinically significant extent (+ 3.8% for recurrence, + 4.3% for progression).

      Conclusion

      In our HR-NMIBC patient cohort treated with BCG, bladder tumor resection weight was associated with disease recurrence and progression. Its addition improves discrimination of standard prognostic factors. Measurement may therefore be considered for routine clinical practice.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sung H
        • Ferlay J
        • Siegel RL
        • et al.
        Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J Clin. 2021; 71: 209-249
        • Richters A
        • Aben KKH
        • Kiemeney LALM.
        The global burden of urinary bladder cancer: an update.
        World J Urol. 2020; 38: 1895-1904
        • Nielsen ME
        • Smith AB
        • Meyer AM
        • et al.
        Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006.
        Cancer. 2014; 120: 86-95
      1. Compérat E, Gontero P, Liedberg F, et al. EAU guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS) 2021.

        • Grimm MO
        • van der Heijden AG
        • Colombel M
        • et al.
        Treatment of high-grade non-muscle-invasive bladder carcinoma by standard number and dose of BCG instillations vs. reduced number and standard dose of BCG instillations: results of the european association of urology research foundation randomised phase III Clinical Trial “NIMBUS”.
        Eur Urol. 2020; 78: 690-698
        • van den Bosch S
        • Alfred Witjes J.
        Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumor progression: a systematic review.
        Eur Urol. 2011; 60: 493-500
        • Miyake M
        • Matsuyama H
        • Teramukai S
        • et al.
        A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables.
        Int J Clin Oncol. 2020; 25: 1364-1376
        • Fernandez-Gomez J
        • Madero R
        • Solsona E
        • et al.
        Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.
        J Urol. 2009; 182: 2195-2203
        • Sylvester RJ
        • van der Meijden AP
        • Oosterlinck W
        • et al.
        Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.
        Eur Urol. 2006; 49: 466-477
        • Kwon DH
        • Song PH
        • Kim HT.
        Multivariate analysis of the prognostic significance of resection weight after transurethral resection of bladder tumor for non-muscle-invasive bladder cancer.
        Korean J Urol. 2012; 53: 457-462
        • De La Peña E
        • Hernández V
        • Blázquez C
        • et al.
        Weight of the resected specimen after transurethral resection as a new predictive variable for recurrence of non-muscle-invasive bladder tumor.
        BJU Int. 2013; 111: E196-E201
        • Fernández-Conejo G
        • de la Peña E
        • Hernández V
        • et al.
        The value of tumor weight as a predictive factor for recurrence and progression in non-muscle invasive bladder cancer.
        Scand J Urol. 2020; 54: 40-45
        • Kamat AM
        • Sylvester RJ
        • Böhle A
        • et al.
        Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the international bladder cancer group.
        J Clin Oncol. 2016; 34: 1935-1944
        • Thomas F
        • Noon AP
        • Rubin N
        • Goepel JR
        • Catto JWF
        Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer.
        European Urology. 2013; 63: 145-154
        • Lamm DL
        • Blumenstein BA
        • Crissman JD
        • et al.
        Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study.
        J Urol. 2000; 163: 1124-1129
        • Miyamoto H
        • Miller JS
        • Fajardo DA
        • Lee TK
        • Netto GJ
        • Epstein JI.
        Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system.
        Pathol Int. 2010; 60: 1-8
        • Li R
        • Sylvester R
        • Dinney CP
        • Kamat AM.
        Letter to the Editor: Bacillus Calmette-Guerin (BCG) treatment failures with non-muscle invasive bladder cancer: a data-driven definition for BCG unresponsive disease.
        Bladder Cancer. 2017; 3: 147-148
        • Lamm D
        • Persad R
        • Brausi M
        • et al.
        Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition.
        J Urol. 2014; 191: 20-27
        • Meira-Machado L
        • Cadarso-Suárez C
        • Gude F
        • Araújo A
        smoothHR: an R package for pointwise nonparametric estimation of hazard ratio curves of continuous predictors.
        Comput Math Methods Med. 2013; 2013745742
        • Racioppi M
        • Cappa E
        • D'Agostino D
        • et al.
        Size of bladder cancers: correlation among different types of measurement.
        Urol Int. 2013; 90: 191-194